Active specific immunotherapy and immunochemotherapy in the treatment of lung and colon cancer.
In this seminar, we describe 1) the immunogen TAA used for lung cancer immunotherapy and the immunogen TAA used for colon cancer immunotherapy, 2) the methods used in the administration of these immunogens in clinical trials of specific active TAA immunotherapy, 3) the results of clinical trials of specific active immunotherapy for lung cancer and for colon cancer patients, 4) the results of immune response monitoring evaluations, and what they indicate, and 5) the way in which certain drugs, selected for their action in the immune system, may be synergistic with specific active TAA immunotherapy, in combination therapy, especially for resected patients of later stages.
Department of Medicine, George Washington Medical Center, Washington, D.C. 20037.
A
A
Hollinshead
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D016233:Immunotherapy, Active; D008175:Lung Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D008297:Male; D008875:Middle Aged
D000276:Adjuvants, Immunologic; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents